By: Ellen Baron, PhD and Oded Ben-Joseph, PhD, MBA
Big guns may have been fired up this week in the financing world with 6 of 12 Biotech IPOs debuting and raising more than $460M dollars.
This figure however is dwarfed by the value of Merger & Acquisitions announced or offers made within healthcare during June to date — and the month isn’t quite over yet!
These deals continue a string of M&A deals announced since the start of 2018, which is headed for record highs — both in the number of deals and the size of those transactions. Overall, healthcare M&A values surged globally during 2017, rising 27% to $332 billion, while the deal count increased 16%. That very robust activity looks to be continuing in 2018.
We strongly believe that despite the recent activity in the public markets, M&A is a far superior path to return on capital for investors — and these numbers support our views.
As a result, we here at Outcome are looking forward to a busy M&A calendar for the remainder of 2018!
The Contract Waterfall: Important Financial Tool in a Federal Government Contractor’s Toolset The contract waterfall plays an important role for both the buyer and the seller in an acquisition and is arguably the most important information that parties will use in the due diligence process What is a Contract Waterfall? The contract waterfall sets forth […]Read More
Outcome Capital Advises Forward Photonics in its Sale April 24, 2020, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in aerospace, defense and government services, technology, life sciences and healthcare, is pleased to announce that Forward Photonics, LLC (the “Company”) has been acquired by an undisclosed private equity […]Read More